Characterisation of a high-affinity VIP receptor in human lung parenchyma  by Schachter, M. et al.
Volume 199, number 1 FEBS 3558 April 1986 
Characterisation of a high-affinity VIP receptor in human 
lung parenchyma 
M. Schachter, K.E.J. Dickinson, C.M. Miles and P.S. Sever 
Department of Clinical Pharmacology, St. Mary’s Hospital Medical School, Norfolk Place, London W2. England 
Received 6 January 1986 
A method is described for preparing human lung parenchymal membranes essentially free of carbon con- 
tamination. Using this technique, a high-affinity 12SI-VIP-binding site has been characterised. The receptor 
density is approx. 200 fmol/mg protein, and the Kd of tzsI-VIP by saturation binding is 200 pM. The dissoci- 
ation kinetics are complex and cannot be described by first-order kinetics. Several VIP-related peptides dis- 
place 1251-VIP from this binding site with a rank order of potency: VIP > rat GRF > PHM, PHI > human 
GRF > secretin > glucagon. Displacement curves of these peptides exhibited slope factors significantly less 
than unity with the exception of human GRF. 
VIP receptor (Human lung) Radioligand binding 
1. INTRODUCTION 
VIP is a potent relaxant of mammalian 
tracheobronchial and pulmonary smooth muscle, 
both in vivo [l-3] and in vitro [4,5]. Dense VIP- 
ergic innervation of both airways and pulmonary 
vessels has been demonstrated in several species in- 
cluding man [6,7]. VIP receptors have also been 
described in lung parenchyma in rat and guinea pig 
using radioligand-binding techniques [8]. Al- 
though the presence of similar receptors has 
been inferred for human lung because of bron- 
chodilator responses in vitro and in vivo and also 
from adenylate cyclase stimulation experiments 
[8,91, such receptors have hitherto not been 
demonstrated by binding studies. The main reason 
has been the excessively high level of non-specific 
binding [8] due to contamination of adult human 
lung by carbon particles. We describe a technique 
for overcoming this problem and we have been 
Abbreviations: VIP, vasoactive intestinal peptide; PHI, 
peptide histidine isoleucine; PHM, peptide histidine 
methionine; PMSF, phenylmethylsulphonyl fluoride; 
GRF, growth hormone-releasing factor 
able to characterise a high-affinity ‘*‘I-VIP- 
binding site in human lung parenchyma using a 
filtration assay system. 
2. MATERIALS AND METHODS 
2.1. Materials 
1251-VIP was obtained from Amersham Interna- 
tional (Amersham, England); unlabelled VIP, 
secretin, PHI, glucagon, Tris, bovine serum 
albumin, polyethyleneimine, leupeptin and soya 
bean trypsin inhibitor from Sigma (Poole, 
England); PHM, rat GRF and human GRF from 
Peninsula Laboratories (St. Helens, England); 
Lymphoprep from Nyegaard and Sepharose 
CL4B from Pharmacia. Other chemicals were of 
Analar grade from British Drug Houses. 
2.2. Methods 
Human lung was obtained at resection or from 
post-mortem specimens obtained within 12 h of 
death. Tissue was rapidly frozen in liquid nitrogen 
and then stored at - 70°C. Approx. 20-30 g lung 
were used at a time for membrane preparation. 
Frozen tissue was placed in cold buffer containing 
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10 mM Tris, 0.25 M sucrose, 5 mM EDTA, 
0.1 mM PMSF, 20 pg/ml soya bean trypsin in- 
hibitor and lOpg/ml leupeptin (pH 7.4). After 
thawing the tissue was minced as finely as possible 
with scissors and then homogenised using a 
Polytron (setting 10, 30 s x 4). The homogenate 
was centrifuged at 1000 x g for 15 min, and the 
supernatant filtered through two layers of 
cheesecloth. The filtrate was centrifuged at 30000 
x g for 15 min and the pellet resuspended in 
Tris/sucrose buffer containing 5 mM EDTA and 
0.1 mM PMSF (approx. 1 ml buffer per 2 g frozen 
wt). The membrane suspension was layered onto 
Lymphoprep (3.5 ml suspension : 1.5 ml Lym- 
phoprep) and centrifuged at 100000 x g for 1 h. 
Membranes were collected at the interface and 
diluted 1: 2 with buffer containing 25 mM Tris and 
5 mM MgC12, pH 7.4, and centrifuged at 45000 x 
g for 15 min. The pellet was resuspended in the 
same buffer and mixed with Sepharose CL-4B gel 
(9 : 1, v/v) previously washed twice in buffer. The 
mixture was centrifuged at 2000 x g for 4 min and 
1pM VIP 
the supernatant, consisting of gel-free membrane 
suspension, was carefully removed. The protein 
content of the suspension was assayed by the 
method of Bradford [lo] and the suspension 
diluted to a protein concentration of 500- 
1000 yg/ml. The final preparation was divided 
into aliquots and stored at -70°C. 
In saturation binding assays, 20~1 membrane 
suspension were incubated with 10,~l 1251-VIP 
(final concentration 0.125-1.25 nM) and 10~1 
buffer or unlabelled VIP (final concentration 
1 PM) to define non-specific binding. The incuba- 
tion buffer consisted of 25 mM Tris, 5 mM MgC12, 
0.5% bovine serum albumin, 0.1% bacitracin. In- 
cubation time was usually 15 min at 37°C. The in- 
cubation was terminated by rapid filtration under 
reduced pressure through Whatman GF/C filters. 
The filters were washed 3 times with 4 ml ice-cold 
buffer containing 50 mM Tris, 0.5 mM EDTA, 
0.2% BSA (pH 7.4). To reduce ligand binding to 
filters, the latter were pre-soaked in 0.3% 
polyethyleneimine. Without this precaution over 
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Fig. 1. Association and dissociation kinetics of ‘2sI-VIP (0.25 nM) binding to lung membranes in the presence (0) and 
absence (0) of 1OOpM GTP. 
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W(rlo of “‘I-VIP was bound to filters in the 
absence of membrane. After filtration, the filter 
discs were dried and counted in a Packard 
Multiprias gamma spectrometer. In kinetic and 
displacement experiments the ‘251-VIP concentra- 
tion was 0.25 nM. Experimental conditions were 
otherwise as described. 
In saturation experiments binding parameters 
were derived using Scatchard analysis [ll]. ICSO 
values in displacement experiments were obtained 
by plotting normalised data on probit paper 
followed by line fitting using linear regression. Ki 
values were calculated according to the equation of 
Cheng and Prusoff [12]. 
3. RESULTS 
At 37°C there is very rapid binding of ‘*‘I-VIP 
to lung parenchymal membranes. Binding reached 
steady state within 2 min (fig. 1). After the addition 
of 1 pM VIP, in the absence of GTP, dissociation 
was not complete and could not be described by 
first-order kinetics. Under these conditions, the 
dissociation curve can be fitted to two components 
with K-r values of 0.178-l and O.Ol-‘, respective- 
ly. In the presence of 1OOgM GTP, first-order 
dissociation kinetics could be applied with a K- 1 of 
0.311-l. 
Table 1 
Inhibition of ‘251-VIP binding to human lung 
membranes: Ki values and Hill slope factors (?rH) 
Ki (nM) nH 
VIP 0.67 f 0.19 0.65 f 0.03 
PHM 27.0 k 26.2 0.69 + 0.01 
PHI 84.0 + 26.2 0.64 f 0.03 
rGRF 26.3 2 6.2 0.81 + 0.08 
hGRF 384 + 23 0.96 + 0.08 
Secretin 1852 + 431 0.73 + 0.08 
Glucagon % 100000 - 
“‘I-VIP concentration: 250 pM for all experiments; 
values are means f SE; n = 3-6 
Over the concentration range studied, Scatchard 
analysis describes a single population of binding 
sites (fig.2). Receptor density is approx. 
200 fmol/mg protein with a Kd of 200 pM. If the 
ligand concentration is increased to more than 
2 nM the Scatchard plot becomes curvilinear, sug- 
gesting the presence of a second binding site of 
lower affinity (not shown). 
Displacement curves for several VIP-related 
peptides are shown in fig.3, and the Ki values and 
Hill factors are summarised in table 1. Peptides 
generally displace from a smaller number of sites 
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Fig.2. Typical saturation binding isotherm of specific ‘251-VIP binding to lung membranes (n = 3, lungs from different 
individuals). Bmax range 183-203 fmol/mg protein. Kd range 0.16-0.25 nM. (Inset) Scatchard plot. 
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Fig.3. Inhibition of ‘z51-VIP (0.25 nM) binding by unlabelled VIP (o), PHM (0), PHI (A), rat GRF (A), human GRF 
(m) and secretin (0). Specific binding is defined by 10e6 M VIP. Typical curves from n = 3-6. 
than unlabelled VIP itself, a common finding 
when the same compound is used as both the 
labelled and the displacing ligand. Only in one 
case, human GRF, does the slope factor approx- 
imate to unity. Other peptides have slope factors 
of about 0.7 although the displacement curve for 
that of GRF is somewhat steeper (nH = 0.81). 
4. DISCUSSION 
We have yet to prepare animal lung membranes 
using an identical protocol, but the density of VIP- 
binding sites in human lung parenchyma is clearly 
less than in rodent species hitherto studied (e.g. 
guinea pig), where receptor density is about 
1 pmol/mg protein (Dickinson, in preparation). 
Using the techniques described we have been Studies in other species have suggested that there 
able to obtain consistently low levels of non- may be a second VIP-binding site in the lung with 
specific binding, usually 10% or less at 250 pM considerably lower affinity (& about 20-25 nM) 
“‘I-VIP. Binding of 12sI-VIP is saturable under [13]. We have not attempted to study this site in 
the conditions noted. Although we have not made man, although adenylate cyclase stimulation 
any attempt o quantitate the residual carbon con- studies suggest that it exists [14]. The shallow 
tamination, these results indicate that it is of displacement curves for unlabelled VIP and other 
minimal significance. Preparations which did not related peptides may reflect the presence of such a 
include the Sepharose purification step were often site, but could be anticipated in any case when 
unsatisfactory in that excessive contamination agonists are used as both radioligands and com- 
usually remained, as judged by high non-specific 
binding and lack of saturability. The very low level 
of filter-bound ligand also contributes to the 
favourable total/non-specific ratio. 
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peting agents. The pharmacological profile of the 
site described resembles that in other mammalian 
lungs, though there are some interesting dif- 
ferences. We have been able to use a wider range 
of peptides than hitherto described in lung VIP 
receptor experiments, and there is an intriguing 
possibility that at least one of these peptides 
(human GRF) might be an antagonist, though not 
a very potent one. At present we have no func- 
tional evidence for this, but if it were confirmed it 
would provide a useful tool for the study of the 
VIP receptor in lung and possibly in other tissues. 
Human GRF may then serve as the starting point 
for the development of structural analogues which 
may be more potent antagonists. 
Another interesting observation relates to the 
kinetic experiments. As previously mentioned, the 
dissociation curve in the presence of excess 
unlabelled VIP cannot adequately be described in 
terms of first-order kinetics. The data suggest hat 
there may be a binding site of very high affinity in 
addition to that described in detail above. Kinetic 
data of this kind have been described for other VIP 
receptors [15-171, and also for insulin [18], but an 
adequate explanation has not yet been proposed. 
No functional correlate for such a site has been 
described in the lung, but in blood vessels VIP is 
a very potent dilator with effective concentrations 
in the picomolar range. It has recently been sug- 
gested that at these low concentrations the 
vasodilator effect of VIP is not mediated by 
adenylate cyclase activation [ 191. 
In conclusion, we have characterised a putative 
high-affinity VIP receptor in human lung paren- 
chymal membranes. The pharmacological charac- 
teristics of this receptor largely resemble those 
described in other mammalian lung VIP receptors. 
The membrane preparation technique may also be 
applicable to binding studies with other ligands, 
particularly in human lung, and the filtration assay 
may prove quicker and more convenient than the 
centrifugation techniques usually used in VIP- 
binding experiments. 
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